Hepatocellular carcinoma (HCC) is estimated to be the third leading cause of cancer-related
mortality and is characterized by low survival rates. Nonalcoholic fatty liver disease (NAFLD) …

Background Emerging data suggest that statins, aspirin and metformin may protect against
hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Background Several studies have demonstrated chemopreventive effects of aspirin against
hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Aims To …

Background Despite the use of new immunotherapies, hepatocellular carcinoma (HCC) has
a poor survival rate. Through multiple molecular mechanisms, aspirin (ASA) has …

Introduction Patients with cirrhosis are at risk of both thrombotic and hemorrhagic events.
Traditional hemostatic tests are inadequate to assess the complex and fragile balance of …

Purpose Aspirin has been suggested to reduce the risk of cancer. However, previous studies
have been inconsistent regarding the relationship between aspirin use and the risk of …

Aim To evaluate the impact of antiplatelet therapy (APT) on the incidence of hepatocellular
carcinoma (HCC) and mortality following its treatment. Methods A systematic literature …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Liver cancer, mainly hepatocellular carcinoma (HCC), remains a major cause of cancer-
related death worldwide. With the global epidemic of obesity, the major HCC etiologies have …